Glauconix is contract research organization (CRO) serving the biopharma industry by providing an innovative service using a patented platform to accelerate glaucoma drug development. With a team highly experienced in the ophthalmic industry. Glauconix is organized around cutting development costs for bringing effective vision saving drugs to market faster. The firm is working on a 3D- Human Tissue Meshwork, a platform technology with applications in medical devices and pharmaceutical development for eyes, kidneys, and the vascular system. Its technology creates 3D genetically customized tissues for various tissue cell types. Glauconix has secured an exclusive license to one US Patent and in the process of securing exclusive licenses to two US Provisional Applications. The technology involved has demonstrated the capability to test the responsiveness of drugs that can increase and decrease pressure in the human eye using a variety of mechanisms. Mimicking the human eye conditions, Glauconixs testing platform provides the most relevant method to assess drug efficacy at the source of glaucoma thus fulfilling an unmet need in glaucoma management. The Company has a fully tested prototype and is scaling-up to meet customers needs.
